ReviewCell biochemistry and biophysics2026
Potential of CAR-Macrophages Derived from Induced Pluripotent Stem Cells (iMacs) for Solid Tumor Therapy.
Review in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Macrophages, a type of immune cell, perform essential functions in the immune system, including controlling inflammation, facilitating tissue healing, and defending the body against disease. However, in solid tumors, they are often reprogrammed into tumor-associated macrophages (TAMs) that support tumors through promotion of blood vessel growth, suppressing immune responses, and promoting tumor spread. Macrophages derived from blood-based sources, including monocytes and peripheral blood mononuclear cells (PBMCs), suffer from three major limitations: inconsistency across different donors, limited survival outside the body, and technical challenges in genetic modification. Consequently, this hinders their research and therapeutic use. Induced Pluripotent Stem Cell-derived macrophages (iMacs) address these issues by providing a renewable and scalable cell source that is genetically flexible while maintaining the natural functions of macrophages. This has opened the possibility for developing chimeric antigen receptor (CAR)-modified iMacs, which combine the ability of macrophages to engulf and destroy cells with precise tumor targeting capabilities. These modified cells can reshape the tumor microenvironment (TME), trigger the body’s targeted immune response, and enhance anti-tumor activity. Evidence from preclinical models demonstrate antigen-dependent anti-tumor activity and immune activation. Initial clinical studies indicate acceptable safety profiles and tumor infiltration in patients with advanced solid tumors. This review explores the recent progress in developing these iMacs therapies against solid tumors and their potential, as well as major biological, safety, and manufacturing challenges to be addressed for clinical use. Addressing these challenges through standardized production methods and combination with existing cancer drugs could establish iMacs as a viable treatment platform for solid tumors.
Indexed as
Identifiers
41739319What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.